Neuren Pharmaceuticals Stock Quote NEU - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

14.485

Bid

14.45

Ask

14.49

Volume

355,317

14.31 Day's Range 14.67

10.90 52 Week Range 170.09

Market Cap

1.85B

Previous Close

14.47

Open

14.43

Last Trade

656

14.45

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

626,000

Shares Outstanding

127,695,676

Dividend Yield

PE Ratio

11.77

Earnings Per Share (EPS)

1.23

Revenue

231.94M

Net Profit

157.08M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.neurenpharma.com

Headquarters

Auckland, Nzl

Founded

Neuren Pharmaceuticals Limited is listed in the Pharmaceutical Preparations sector of the Australian Stock Exchange with ticker NEU. The last closing price for Neuren Pharmaceuticals was AUD14.47. Over the last year, Neuren Pharmaceuticals shares have traded in a share price range of AUD 10.90 to AUD 170.09.

Neuren Pharmaceuticals currently has 127,695,676 shares outstanding. The market capitalization of Neuren Pharmaceuticals is AUD1.85 billion. Neuren Pharmaceuticals has a price to earnings ratio (PE ratio) of 11.77.

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment...

With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced...

FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome...

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the A...

-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome-- Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in...

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development & Com...

-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren...

American Stock Exchange to Trade Options on Five New Securities

NEW YORK, April 12 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Thursday, April 13, 2006 on the following Nasdaq Stock Market and New York Stock...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.685	4.96376811594	13.8	14.83	13.62	759876	14.33560334	DE
4	2.185	17.7642276423	12.3	14.83	10.9	602242	12.79401615	DE
12	1.535	11.8532818533	12.95	17.94	10.9	626000	13.52883959	DE
26	-5.965	-29.1687041565	20.45	170.09	10.9	562382	14.10349178	DE
52	-9.025	-38.387920034	23.51	170.09	10.9	513521	16.97809339	DE
156	11.285	352.65625	3.2	170.09	3.04	467011	13.21612208	DE
260	11.655	411.83745583	2.83	170.09	0.965	350490	10.97653468	DE

NEU - Frequently Asked Questions (FAQ)

What is the current Neuren Pharmaceuticals share price?

The current share price of Neuren Pharmaceuticals is AUD 14.485

How many Neuren Pharmaceuticals shares are in issue?

Neuren Pharmaceuticals has 127,695,676 shares in issue

What is the market cap of Neuren Pharmaceuticals?

The market capitalisation of Neuren Pharmaceuticals is AUD 1.85B

What is the 1 year trading range for Neuren Pharmaceuticals share price?

Neuren Pharmaceuticals has traded in the range of AUD 10.90 to AUD 170.09 during the past year

What is the PE ratio of Neuren Pharmaceuticals?

The price to earnings ratio of Neuren Pharmaceuticals is 11.77

What is the cash to sales ratio of Neuren Pharmaceuticals?

The cash to sales ratio of Neuren Pharmaceuticals is 7.97

What is the reporting currency for Neuren Pharmaceuticals?

Neuren Pharmaceuticals reports financial results in NZD

What is the latest annual turnover for Neuren Pharmaceuticals?

The latest annual turnover of Neuren Pharmaceuticals is NZD 231.94M

What is the latest annual profit for Neuren Pharmaceuticals?

The latest annual profit of Neuren Pharmaceuticals is NZD 157.08M

What is the registered address of Neuren Pharmaceuticals?

The registered address for Neuren Pharmaceuticals is SUITE 201, 697 BURKE ROAD, CAMBERWELL, VIC 3124, AUCKLAND

What is the Neuren Pharmaceuticals website address?

The website address for Neuren Pharmaceuticals is www.neurenpharma.com

Which industry sector does Neuren Pharmaceuticals operate in?

Neuren Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ATHOAlterity Therapeutics Limited	AUD 0.012 (200.00%)	109.48M
ATHAlterity Therapeutics Ltd	AUD 0.018 (125.00%)	445.78M
NRZONeuRizer Ltd	AUD 0.002 (100.00%)	440k
VPRVolt Group Ltd	AUD 0.002 (100.00%)	5.01k
SFGSeafarms Group Limited	AUD 0.002 (100.00%)	132.21k
HYDHydrix Limited	AUD 0.015 (-31.82%)	1.92M
CNJConico Ltd	AUD 0.007 (-30.00%)	4.34M
FG1OFlynn Gold Limited	AUD 0.005 (-28.57%)	325.02k
MIOMacarthur Minerals Ltd	AUD 0.031 (-27.91%)	277.59k
ACWODActinogen Medical Limited	AUD 0.008 (-27.27%)	200k
ATHAlterity Therapeutics Ltd	AUD 0.018 (125.00%)	445.78M
ATHOAlterity Therapeutics Limited	AUD 0.012 (200.00%)	109.48M
ZIPZip Co Limited	AUD 2.44 (-25.15%)	80.5M
VFXVisionflex Group Ltd	AUD 0.0025 (-16.67%)	76.79M
EELENRG Elements Ltd	AUD 0.001 (0.00%)	76.35M